Skip to main content
Equibles

Point72 Asset Management, L.P.

Position in ADCT — ADC Therapeutics SA

CIK 1603466 STAMFORD, CT
Back to ADCT Full portfolio

Position in ADCT

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$3,904,584
-$8,778,399 QoQ
Shares Held
3,649,144
+7.9% QoQ
Ownership
2.86%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#6
of 113 holders
Holding Since
Dec 2022
6 quarters on record
Voting authority Sole 0% Shared 100% None 0%

Common Shares in ADCT Over Time

Shares Held

Position Value (USD)

Derivatives in ADCT

reported options exposure · as of Jun 30, 2026
CallValue
$28,248
CallShares
26,400
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - Specialty & Generic

Healthcare · as of Jun 30, 2026

Point72 Asset Management, L.P. holds $450,936,643 across 22 Drug Manufacturers - Specialty & Generic names. ADCT ranks #12 (0.9% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 UTHR
UNITED THERAPEUTICS Corp
 201,159 $108,993,980
2 HLN
Haleon plc
 9,264,255 $86,435,499
3 LNTH
Lantheus Holdings, Inc.
 629,806 $69,870,677
4 INDV
Indivior Pharmaceuticals, Inc.
 1,250,639 $51,313,718
5 KNSA
Kiniksa Pharmaceuticals International, plc
 659,493 $42,174,577
6 TEVA
Teva Pharmaceutical Industries Ltd
 1,059,778 $35,905,278
7 BHC
Bausch Health Companies Inc.
 2,235,821 $11,022,597
8 EOLS
Evolus, Inc.
 1,508,518 $10,469,114

All Filings in ADCT

Export CSV
8 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $28,248 26,400
2026-06-30 $3,904,584 3,649,144
2026-03-31 $99,000 26,400
2026-03-31 $12,682,983 3,382,129
2025-12-31 $17,701,598 5,014,617
2025-09-30 $32,542,604 8,135,651
2025-06-30 $20,806,603 7,763,658
2022-12-31 $2,705,280 704,500